Pulmonary Hypertension

Pulmonary Arterial Hypertension Market Thriving Technology, Latest Industry Expansion ,Potential Gro - PharmiWeb.com Pulmonary Arterial Hypertension Market Thriving Technology, Latest Industry Expansion ,Potential Gro - PharmiWeb.com Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine - Business Wire Pulmonary Arterial Capacitance Is a Strong Predictor of Mortality in PAH, PH-LHD - AJMC.com Managed Markets Network Pulmonary Arterial Hypertension Market Thriving Technology, Latest Industry Expansion ,Potential Gro - PharmiWeb.com Posted: 01 Mar 2021 12:00 AM PST Pulmonary hypertension or PAH is type of blood pressure that affects the arteries in lungs and right side of the heart. In this condition, blood pressure rises in the pulmonary artery, vein, or capillaries (collectively known as lung vasculature), which might lead to shortness of breath, fainting, leg swelling, an...

Can Anxiety Cause High Blood Pressure? - Healthline Can Anxiety Cause High Blood Pressure? - Healthline Posted: 30 Mar 2021 01:21 PM PDT According to the Anxiety & Depression Association of America (ADAA) , anxiety disorders affect more than 40 million adults every year in the United States. Anxiety can cause a wide range of physical symptoms, including an increase in blood pressure levels. Although anxiety isn't linked to chronic high blood pressure, both short-term and chronic anxiety may cause your blood pressure to spike. In this article, we'll explore the link between anxiety and high blood pressure and treatment options for both. Fortunately, anxiety doesn't cause chronic high blood pressure. However, it can lead to a short-term increase in blood pressure. When you begin to feel anxious because of a stressful situation, your body enters fight-or-flight mode. This happens due to the activation of your ...

Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine - Business Wire Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine - Business Wire Posted: 29 Mar 2021 05:00 AM PDT WHIPPANY, N.J.--( BUSINESS WIRE )--Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE ( R iociguat r E placing P DE-5i therapy eva L uated A gainst C ontinued PDE-5i th E rapy) study in which intermediate-risk adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1) transitioned to Adempas ® (riociguat) after an insufficient response to phosphodiesterase-5 inhibitor (PDE5i) therapy. Specifically, 41 percent (45/111) of patients receiving Adempas therapy achieved the composite primary endpoint of clinical improvement in the absence of clinical worsening, compared with 20 percent (23/113) in the PDE5i gr...

[Full text] Prognostic Significance of Systemic Arterial Stiffness Evaluated by Ca | VHRM - Dove Medical Press [Full text] Prognostic Significance of Systemic Arterial Stiffness Evaluated by Ca | VHRM - Dove Medical Press Posted: 09 Mar 2021 12:00 AM PST Department of Symptomatic Hypertension, "National Scientific Center "The M.D. Strazhesko Institute of Cardiology"" of National Academy of Medical Science, Kyiv, Ukraine Correspondence: Ganna D Radchenko Department of Symptomatic Hypertension, "National Scientific Center "The M.D. Strazhesko Institute of Cardiology"" of National Academy of Medical Science, 5, Narodnogo Opolchenia Str, Kyiv, 03680, Ukraine Tel +380 667128405 Email rganna@bigmir.net Background: In a previous study, the cardio-ankle vascular index (CAVI) was increased significantly in idiopathic pulmonary arterial hypertension (IPAH) patients compared to the healthy group and did not much d...